The design and synthesis of benzimidazolyl and indolyl linked 𝛼-alkoxy phenylpropanoic acid derivatives and the 𝛽-keto ester analogues in an effort to develop novel peroxisome proliferator activated receptors ligands expected to exhibit PPAR𝛼 and PPAR𝛾 partial agonism in the management of hyperglycemia and hyperlipidemia for the treatment of type 2 diabetes is reported. Computational validation of the designed molecules through activity prediction and docking studies showed expected results.
Volume 135, 2023
Continuous Article Publishing mode
Click here for Editorial Note on CAP Mode